USPTO serial 85014822
AUXX
Reviewed by CopyMark Law Group
Reg. 4204273Status 710
- Filing date
- Status date
- Registration date
- Sep 11, 2012
- Examiner
- HAMPTON, CHARISMA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with AUXX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Dangan, Galway, IE
Dangan, Galway, IE
Dangan, Galway, IE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cynthia C. Weber
LEIGH ANN LINDQUIST SUGHRUE MION PLLC2100 PENNSYLVANIA AVENUE NWWASHINGTON, DC 20037-3202UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary delivery apparatus, equipment, instruments, devices and systems, namely, drug delivery agents in the form of tablets, powders, capsules, pills, caplets, liquid drops and sachets that provide controlled release of active ingredients for a wide variety of medicaments, pharmaceuticals, vaccines and drugs for delivery thereof intradermally, transdermally, subcutaneously or otherwise through the skin; transdermal patches for use in the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders,diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases containing medicaments, pharmaceuticals, vaccines and drugs for delivery thereof intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches for use in the treatment of viral, metabolic, endocrine,musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders,diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression,eating disorders, anorexia, obesity, infectious diseases and bone diseases containing medicaments, pharmaceuticals, vaccines and drugs intradermally, transdermally, subcutaneously or otherwise through the skin; cartridges sold pre-filled with medicaments, pharmaceuticals, vaccines and drugs for the treatment of viral,metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases used in medical and veterinary delivery apparatus, equipment, instruments, devices and systems; and cartridges sold pre-filled with medicaments, pharmaceuticals, vaccines and drugs for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal and dermatological diseases and disorders, immune system related diseases and disorders, cancer, autoimmune diseases and disorders, diabetes, kidney diseases and disorders, ocular diseases and disorders, bacteria-based diseases and disorders, influenza, psychiatric diseases and disorders, voice disorders, digestive disorders, vulvovaginal disorders, congenital disorders, depression, eating disorders, anorexia, obesity, infectious diseases and bone diseases used in micro-needle devices | SECTION 8 - CANCELLED | — |
| 010 | Transdermal drug delivery patches sold without medication; medical and veterinary delivery apparatus, equipment, instruments, devices and systems, namely, drug delivery patches sold without medication, electronic-kinetic transdermal drug delivery control unit for the treatment of diseases for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; medical and veterinary apparatus, equipment, instruments, devices and systems, namely, micro-needles for medical use; medical needles and introducers, drainage tubes for medical purposes and wound suction apparatus for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; drug delivery patches sold without medication for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches sold without medication for the treatment of diseases for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle devices, namely, active transdermal micro-needle drug delivery patches sold without medication for the treatment of diseases for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needles for delivering medicaments, pharmaceuticals, vaccines and other substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needles for medical use for withdrawing bodily substances intradermally, transdermally, subcutaneously or otherwise through the skin; micro-needle elements, namely, needle-free injection systems, needle-based injection systems and injection instruments with needles for use in such micro-needle devices; cartridges sold empty specially designed for holding medicaments, pharmaceuticals, vaccines and drugs for use in medical and veterinary delivery apparatus, equipment, instruments, devices and systems; cartridges sold empty specially designed for holding medicaments, pharmaceuticals, vaccines and drugs used in micro-needle devices; needles for medical and veterinary purposes; diagnostic apparatus, equipment, instruments, devices and systems, namely, blood pressure monitors, hematology analyzers for medical diagnostic uses, haemostats and dialysis machines for medical and veterinary purposes | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 12, 2019 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 11, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 11, 2012 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 27, 2012 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jun 27, 2012 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 25, 2012 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 15, 2012 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| May 15, 2012 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 20, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 20, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 29, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 15, 2012 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 9, 2012 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Feb 9, 2012 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 1, 2012 | DMCC | DATA MODIFICATION COMPLETED | — |
| Jan 5, 2012 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Nov 9, 2011 | GEA1 | NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | — |
| Nov 9, 2011 | GECD | ACTION DENYING REQ FOR RECON E-MAILED | — |
| Nov 9, 2011 | CNCF | ACTION CONTINUING FINAL - COMPLETED | — |
| Sep 12, 2011 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Sep 12, 2011 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Sep 12, 2011 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Aug 26, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 26, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 26, 2011 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 10, 2011 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 10, 2011 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 10, 2011 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 2, 2011 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 2, 2011 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 31, 2011 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 29, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 22, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 9, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 9, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2010 | ALIE | ASSIGNED TO LIE | — |
| May 25, 2010 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 20, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 19, 2010 | NWAP | NEW APPLICATION ENTERED | — |